Premium
High cyclin A expression, but not Ki67, is associated with early recurrence in desmoid tumors
Author(s) -
Santti Kirsi,
Ihalainen Hanna,
Rönty Mikko,
Böhling Tom,
Karlsson Christina,
Haglund Caj,
Tarkkanen Maija,
Blomqvist Carl
Publication year - 2018
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25121
Subject(s) - medicine , immunohistochemistry , cyclin d3 , fibromatosis , soft tissue , pathology , cyclin , oncology , cell cycle , cancer
Background and Objectives Desmoid tumors are soft‐tissue tumors originating from myofibroblasts with a tendency to recur after surgery. High expression of proliferation markers is associated with shortened progression‐free and/or overall survival in many neoplasms, including soft‐tissue sarcomas. We investigated the prognostic role of cyclin A and Ki67 in desmoid tumors by immunohistochemistry. Methods The study included 76 patients with desmoid tumor operated at Helsinki University Hospital between 1987 and 2011. A tissue micro array (TMA) was constructed and the TMA sections were immunostained with cyclin A and Ki67 antibodies. A computer‐assisted image analysis was performed. Results Cyclin A expression was evaluable in 74 and Ki67 in 70 patients. Cyclin A immunopositivity varied from 0% to 9.9%, with a mean of 1.9%. Cyclin A expression correlated significantly with Ki67. Cyclin A expression was associated with recurrence‐free survival (HR 1.9, 95% CI = 1.1‐3.2, P = .02), as were positive margin (HR 6.0, 95% CI = 1.6‐22.5, P = .008) and extremity location (HR 5.3, 95% CI = 1.7‐16.8, P = 0.005). Ki67 immunopositivity varied from 0.33% to 13.8%, with a mean of 4.6%, but had no significant prognostic impact (HR 1.1, P = .2). Conclusions Our study indicates that cyclin A may be a new prognostic biomarker in surgically treated desmoid tumors.